Background: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. Methods: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (≥65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. Results: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir+ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively). Conclusion: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults. Cite this article as: Önlen Y, Bal T, Çabalak M, et al. Efficacy and safety of direct-acting antivirals in elderly patients with chronic hepatitis C: A nationwide real-life, observational, multicenter study from Turkey. Turk J Gastroenterol. 2022;33(10):862-873.
19 December 2019 in Turkish Journal of Parasitology
Malaria is an infection disease caused by plamodium parasite. Sporadic cases have not been observed since 2011, but imported cases still present owing to travel. In this study, we aimed to evaluate labotauary and clinical findings patients with malaria who were hospitalized and treated in our hospital. Between January 2012-November 2018, a total of 31 adult patients was evaluated retrospectively, in terms of their epidemiological, physical examination and laboratory findings, complaints, countries they traveled to, prophylaxis and treatment that they received. Data of the patients were taken from the hospital’s database. A total of 31 cases were diagnosed as having malaria. The causative microorganism was P. falciparum in 54.83% (17/31) of the patients, P. vivax in 32.25% (10/31), and P. falciparum-P. vivax co-infection in 12.9% (4/31) of the patients. Co-infections were excluded from the study. None of the cases had used prophylactic drugs for prevention of malaria. All of the cases suffered from chills with fever. The most frequently encountered pathologic laboratory findings were thrombocytopenia and leucopenia. Antibiotics had been initiated in 51.85% (14/27) of the patients with non-specific diagnoses. Rapid antigen test was used in 8148% (22/27) of cases. None of cases needed intensive care. It is important to inform persons who plan to visit malaria endemic areas about malaria and to make them take appropriate prophylaxis against malaria. Although P. falciparum which has a high mortality rate may be considered in the first plan, P. vivax, treatment of which is different due to risk of relapse, should not be overlooked.
Objective: Tuberculosis (TB) is the most important opportunistic infection and one of the leading causes of death in individuals living with human immunodeficiency virus (HIV). Treatment of HIV/TB coinfected patients is more complicated than that of individuals living with HIV only. We aimed to determine the epidemiological characteristics of HIV/TB coinfected patients and the factors affecting TB treatment success. Methods: This retrospective study was conducted between January 2006 and December 2022. Among individuals living with HIV, those aged ≥18 years and with active tuberculosis were included in the study. Sociodemographic, clinical and laboratory findings of HIV/TB coinfected patients were recorded from their files. Patients were divided into two groups according to TB treatment response. The statistical significance level was accepted as p <0.05 in comparison of the two groups. Results: Active TB disease was detected in 78 (%8.4) of 931 individuals living with HIV. A total of 74 patients were included in the study. The average age of the patients was 42.84±12.91 years (range 20-78); 64 (86.5%) were male, and 32 (43.2%) were unemployed. Before TB treatment, 36 (48.6%) of the individuals living with HIV had CD4+ <100 cells/mm3, 10 (13.5%) had negative viral load and only 12 (16.2%) had received antiretroviral treatment (ART). Of these patients, 42 (56.8%) were evaluated as pulmonary TB and 32 (43.2%) as extrapulmonary TB. TB treatment was successful in 49 (%66.2) of the patients; 15 (%20.3) died, 5 (%6.8) received insufficient treatment, 2 (%2.7) were lost to follow-up, and 3 (%4.1) were transferred to another centre. Unsuccessful TB treatment outcomes were associated with a higher mortality rate (20.3%) and increasing age (p<0.05). Conclusion: In our study, the success rate of TB treatment in HIV/TB coinfected individuals was determined as 66.2%. Our findings were lower than World Health Organization targets. The high mortality rate and the advancing age of the patients were determined to be the most critical factors affecting the success of the TB treatment. We conclude that more attention should be paid to HIV/TB coinfected patients, strategies should be developed to ensure early diagnosis, and more comprehensive and prospective studies on this subject need to be conducted in our country.
15 November 2022 in Turkish Journal of Gastroenterology
Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization’s objective of eliminating viral hepatitis Cite this article as: Sarıgül Yıldırım F, Üser Ü, Sarı ND, et al. In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkey. Turk J Gastroenterol. 2022;33(11):971-978
26 September 2024 in Infectious Diseases and Clinical Microbiology
Henoch-Schönlein purpura (HSP) is a systemic small-vessel vasculitis characterized by involvement in the skin, kidney, and gastrointestinal system. It is frequently seen in children, accounting for 90% of cases. HSP is less common in adults. Cutaneous involvement is the most common presentation, and in some cohorts, adult HSP is more severe and has worse
26 December 2024 in Flora the Journal of Infectious Diseases and Clinical Microbiology